Browse PPP1CB

Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Nucleus, nucleoplasm Nucleus, nucleolus Note=Highly mobile in cells and can be relocalized through interaction with targeting subunits. In the presence of PPP1R8 relocalizes from the nucleus to nuclear speckles.
Domain PF00149 Calcineurin-like phosphoesterase
PF16891 Serine-threonine protein phosphatase N-terminal domain
Function

Protein phosphatase that associates with over 200 regulatory proteins to form highly specific holoenzymes which dephosphorylate hundreds of biological targets. Protein phosphatase (PP1) is essential for cell division, it participates in the regulation of glycogen metabolism, muscle contractility and protein synthesis. Involved in regulation of ionic conductances and long-term synaptic plasticity. Component of the PTW/PP1 phosphatase complex, which plays a role in the control of chromatin structure and cell cycle progression during the transition from mitosis into interphase. In balance with CSNK1D and CSNK1E, determines the circadian period length, through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. May dephosphorylate CSNK1D and CSNK1E. Dephosphorylates the 'Ser-418' residue of FOXP3 in regulatory T-cells (Treg) from patients with rheumatoid arthritis, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208).

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0000271 polysaccharide biosynthetic process
GO:0000272 polysaccharide catabolic process
GO:0005976 polysaccharide metabolic process
GO:0005977 glycogen metabolic process
GO:0005978 glycogen biosynthetic process
GO:0005979 regulation of glycogen biosynthetic process
GO:0005980 glycogen catabolic process
GO:0005981 regulation of glycogen catabolic process
GO:0005996 monosaccharide metabolic process
GO:0006006 glucose metabolic process
GO:0006073 cellular glucan metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006109 regulation of carbohydrate metabolic process
GO:0006112 energy reserve metabolic process
GO:0006470 protein dephosphorylation
GO:0007623 circadian rhythm
GO:0009250 glucan biosynthetic process
GO:0009251 glucan catabolic process
GO:0009314 response to radiation
GO:0009416 response to light stimulus
GO:0009648 photoperiodism
GO:0009649 entrainment of circadian clock
GO:0009894 regulation of catabolic process
GO:0010675 regulation of cellular carbohydrate metabolic process
GO:0010906 regulation of glucose metabolic process
GO:0010962 regulation of glucan biosynthetic process
GO:0015980 energy derivation by oxidation of organic compounds
GO:0016051 carbohydrate biosynthetic process
GO:0016052 carbohydrate catabolic process
GO:0016311 dephosphorylation
GO:0019318 hexose metabolic process
GO:0031329 regulation of cellular catabolic process
GO:0032881 regulation of polysaccharide metabolic process
GO:0032885 regulation of polysaccharide biosynthetic process
GO:0032922 circadian regulation of gene expression
GO:0033692 cellular polysaccharide biosynthetic process
GO:0034637 cellular carbohydrate biosynthetic process
GO:0042752 regulation of circadian rhythm
GO:0043153 entrainment of circadian clock by photoperiod
GO:0043255 regulation of carbohydrate biosynthetic process
GO:0043467 regulation of generation of precursor metabolites and energy
GO:0043470 regulation of carbohydrate catabolic process
GO:0043471 regulation of cellular carbohydrate catabolic process
GO:0044042 glucan metabolic process
GO:0044247 cellular polysaccharide catabolic process
GO:0044262 cellular carbohydrate metabolic process
GO:0044264 cellular polysaccharide metabolic process
GO:0044275 cellular carbohydrate catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0048511 rhythmic process
GO:0070873 regulation of glycogen metabolic process
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004722 protein serine/threonine phosphatase activity
GO:0016791 phosphatase activity
GO:0017018 myosin phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
GO:0050115 myosin-light-chain-phosphatase activity
Cellular Component GO:0000164 protein phosphatase type 1 complex
GO:0000781 chromosome, telomeric region
GO:0000784 nuclear chromosome, telomeric region
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0008287 protein serine/threonine phosphatase complex
GO:0030055 cell-substrate junction
GO:0034708 methyltransferase complex
GO:0035097 histone methyltransferase complex
GO:0042587 glycogen granule
GO:0044454 nuclear chromosome part
GO:0070688 MLL5-L complex
GO:0072357 PTW/PP1 phosphatase complex
GO:0098687 chromosomal region
GO:1903293 phosphatase complex
> KEGG and Reactome Pathway
 
KEGG hsa03015 mRNA surveillance pathway
hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04114 Oocyte meiosis
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04270 Vascular smooth muscle contraction
hsa04390 Hippo signaling pathway
hsa04510 Focal adhesion
hsa04611 Platelet activation
hsa04720 Long-term potentiation
hsa04728 Dopaminergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway
hsa04921 Oxytocin signaling pathway
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-400253: Circadian Clock
R-HSA-2173788: Downregulation of TGF-beta receptor signaling
R-HSA-69275: G2/M Transition
R-HSA-163560: Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627117: RHO GTPases Activate ROCKs
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173789: TGF-beta receptor signaling activates SMADs
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PPP1CB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PPP1CB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 3.84; FDR: 0.029 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PPP1CB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0070.977
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0080.998
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0110.995
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2770.394
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3950.853
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1260.964
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1430.77
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1370.949
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1410.953
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1890.914
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6320.815
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0210.732
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PPP1CB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PPP1CB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PPP1CB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PPP1CB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PPP1CB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PPP1CB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PPP1CB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPPP1CB
Nameprotein phosphatase 1, catalytic subunit, beta isozyme
Aliases PP1B; PP-1B; PP1beta; protein phosphatase 1, catalytic subunit, beta isoform; HEL-S-80p; PPP1CD; epididymis ......
Chromosomal Location2p23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PPP1CB collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.